Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia

Blood

Volumn 111, Issue 5, 2008, Pages 2790-2796

  Agrawal, Samir G ^a,b,c,e   Liu, Feng Ting ^a   Wiseman, Catherine ^b   Shirali, Sima ^d   Liu, Hongxiang ^d   Lillington, Debra ^c   Du, Ming Qing ^d   Syndercombe Court, Denise ^a   Newland, Adrian C ^a,b   Gribben, John G ^a,c   Jia, Li ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; PROTEASOME; PROTEIN BAX; PROTEIN KINASE ZAP 70; CD38 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; ZAP70 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN STABILITY; B CELL LEUKEMIA; METABOLISM; PROTEIN PROCESSING; SURVIVAL; THERMODYNAMICS; TIME; TREATMENT OUTCOME;

ANTIGENS, CD38; BCL-2-ASSOCIATED X PROTEIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MEMBRANE GLYCOPROTEINS; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN PROCESSING, POST-TRANSLATIONAL; SURVIVAL ANALYSIS; THERMODYNAMICS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 41949096727     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-10-110460     Document Type: Article

References (35)

1. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840-1847.
2. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848-1854.
3. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764-1775.
4. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet. 2004;363:105-111.
5. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004;351:893-901.
6. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
7. Pettitt AR, Sherrington PD, Stewart G, Cawley JC, Taylor AM, StankovicT. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood. 2001;98:814-822.
8. Castro JE, Prada CE, Loria O, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood. 2005;106:2506-2512.
9. Chen L, Apgar J, Huynh L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood. 2005;105:2036-2041.
10. Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood. 2005;105:3042-3050.
11. Deglesne PA, Chevallier N, Letestu R, et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap-70 expression. Cancer Res. 2006;66:7158-7166.
12. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63:1129-1136.
13. Breitschopf K, Zeiher AM, Dimmeler S. Ubiquitin-mediated degradation of the proapoptotic active form of bid. Afunctional consequence on apopto-sis induction. J Biol Chem. 2000;275:21648-21652.
14. Chang YC, Lee YS, Tejima T, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ. 1998;9:79-84.
15. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA. 2000;97:3850-3855.
16. Lotan R, Rotem A, Gonen H, et al. Regulation of the proapoptotic ARTS protein by ubiquitin-medi-ated degradation. J Biol Chem. 2005;280:25802-25810.
17. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107:257-264.
18. Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC. Overexpression of the Bcl-2 protein increases the half-life of p21Bax. J Biol Chem. 1995;270:26049-26052.
19. McConkey DJ, Chandra J, Wright S, et al. Apoptosis sensitivity in chronic lymphocytic leukemia is determined by endogenous endonuclease content and relative expression of BCL-2 and BAX. J Immunol. 1996;156:2624-2630.
20. Liu F-T, Agrawal SG, Gribben JG, et al. Bort-ezomib blocks Bax degradation in malignant B cells during treatment with TRAIL. Blood. 2008;111:2797-2805.
21. Wendt J, von Haefen C, Hemmati P, Belka C, Dorken B, Daniel PT. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene. 2005;24:4052-4064.
22. Fecker LF, Geilen CC, Tchernev G, et al. Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis. J Invest Dermatol. 2006;126:1366-1371.
23. Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M. Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer. 1996;69: 114-149.
24. Molica S, Dattilo A, Giulino C, Levato D, Levato L. Increased bcl-2/bax ratio in B-cell chronic lym-phocytic leukemia is associated with a progressive pattern of disease. Haematologica. 1998;83: 1122-1124.
25. Bannerji R, Kitada S, Flinn IW, et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol. 2003;21:1466-1471.
26. Starczynski J, Pepper C, Pratt G, et al. Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. J Clin Oncol. 2005;23:1514-1521.
27. Johnston JB, Daeninck P, Verburg L, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk Lymphoma. 1997;26:435-449.
28. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002;16:1045-1052.
29. Schwartz R, Davidson T. Pharmacology, pharma-cokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004;18(14 Suppl 11):14-21.
30. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617.
31. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/bortezomib, doxorubi-cin and dexamethasone) for previously untreated patients with multiple myeloma. Brit J Haematol. 2005;129:755-762.
32. Faderl S, Rai K, Gribben J, et al. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer. 2006;107:916-924.
33. Kabore AF, Sun J, Hu X, McCrea K, Johnston JB, Gibson SB. The TRAIL apoptotic pathway mediates proteasome inhibitor induced apoptosis in primary chronic lymphocytic leukemia cells. Apoptosis. 2006;11:1175-1193.
34. Duechler M, Linke A, Cebula B, et al. In vitro cytotoxic effect of proteasome inhibitor bortezomib in combination with purine nucleoside analogues on chronic lymphocytic leukaemia cells. Eur J Haematol. 2005;74:407-417.
35. Smolewski P, Duechler M, Linke A, et al. Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells. Leuk Res. 2006;30:1521-1529.